Pfizer (PFE) stock tumbled Tuesday, crashing into its 50-day line, after the drugmaker missed Wall Street’s earnings forecast following a suite of acquisitions. Leerink Partners analyst David Risinger says it’s “not a major surprise.” Pfizer spent $10 billion to acquire obesity drugmaker Metsera after a bidding war with Novo Nordisk (NVO). It has also signed a handful of licensing deals…
